David Stroncek
Overview
Explore the profile of David Stroncek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
90
Citations
1791
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dreyzin A, Shao L, Cai Y, Lee Han K, Prochazkova M, Gertz M, et al.
Mol Ther
. 2025 Mar;
PMID: 40087865
Although CAR T-cell therapy is increasingly used to treat relapsed B-cell acute lymphoblastic leukemia (ALL), 20-30% of patients do not respond, and few clinical predictors of response have been established,...
2.
Vo P, Srinivasan R, Purev E, McDuffee E, Worthy T, Shalabi R, et al.
Bone Marrow Transplant
. 2024 Sep;
59(12):1777-1779.
PMID: 39251835
No abstract available.
3.
Mamo T, Cox C, Demorest C, Fontaine M, Hubel A, Kelley L, et al.
Cytotherapy
. 2024 Jul;
26(12):1522-1531.
PMID: 39066775
Background And Aim: An essential aspect of ensuring availability and stability of mesenchymal stem/stromal cells (MSCs) products for clinical use is that these cells are cryopreserved before individual infusion into...
4.
Mamo T, Dreyzin A, Stroncek D, McKenna D
Clin Chem
. 2024 Jan;
70(1):116-127.
PMID: 38175598
Background: Chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment of hematologic malignancies and holds promise for solid tumors. While responses to CAR T-cell therapy have surpassed other available options...
5.
Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy
Kaczanowska S, Murty T, Alimadadi A, Contreras C, Duault C, Subrahmanyam P, et al.
Cancer Cell
. 2023 Dec;
42(1):35-51.e8.
PMID: 38134936
Chimeric antigen receptor T cells (CAR-Ts) have remarkable efficacy in liquid tumors, but limited responses in solid tumors. We conducted a Phase I trial (NCT02107963) of GD2 CAR-Ts (GD2-CAR.OX40.28.z.iC9), demonstrating...
6.
Shaz B, Schafer R, Fontaine M, Norris P, McKenna D, Jin P, et al.
Cytotherapy
. 2023 Dec;
26(6):531-539.
PMID: 38043052
Background Aims: Culture-derived mesenchymal stromal cells (MSCs) exhibit variable characteristics when manufactured using different methods, source material and culture media. The purpose of this multicenter study was to assess the...
7.
Tran M, Cai Y, Stroncek D
Transplant Cell Ther
. 2023 Oct;
30(1):120.e1-120.e10.
PMID: 37797720
Unrelated donor peripheral blood stem cell (PBSC) products often require transport to distant locations, which may take up to 72 hours. Temperature is an important variable that can be controlled...
8.
Holland E, Yates B, Steinberg S, Yuan C, Wang H, Annesley C, et al.
Transplant Cell Ther
. 2023 Jul;
29(9):574.e1-574.e10.
PMID: 37394115
Outcomes for post-chimeric antigen receptor (CAR) T cell therapy (CART) relapse are poor. The utilization of a unique CAR T cell construct for post-CART failure is increasing, but this approach...
9.
Dreyzin A, Panch S, Shalabi H, Yates B, Highfill S, Jin P, et al.
Mol Ther Methods Clin Dev
. 2023 Jan;
28:51-61.
PMID: 36620075
Cryopreservation of chimeric antigen receptor (CAR) T cells facilitates shipment, timing of infusions, and storage of subsequent doses. However, reports on the impact of cryopreservation on CAR T cell efficacy...
10.
Trepanier P, Fournier D, Simard C, Fontaine M, Stroncek D, Takanashi M, et al.
Transfusion
. 2022 Jun;
62(8):1595-1601.
PMID: 35770742
Background: The IL-3-pSTAT5 assay, a new, rapid, and standardized flow-cytometry-based assay may compensate for several limitations of the colony-forming unit (CFU) assay typically used for stem cell potency assessments of...